The earnings call highlighted strong financial performance and significant progress in international market expansion and clinical trials, particularly for setmelanotide in acquired hypothalamic obesity. However, challenges remain in the Prader-Willi Syndrome trial and rising operating expenses.

Company Guidance -

Q3 2025

In the Q2 2025 earnings call for Rhythm Pharmaceuticals, several key metrics and future expectations were discussed. The company reported a 29% increase in global revenue, reaching $48.5 million, with U.S. revenue contributing $32 million and international revenue $16.5 million. The company achieved a 38% growth in the cumulative number of IMCIVREE prescribers for BBS patients from Q2 2024 to Q2 2025. They also observed a 9% growth in prescribers from Q1 to Q2 2025. Rhythm Pharmaceuticals successfully completed an oversubscribed equity offering, raising $189.2 million, and ended Q2 with $291 million in cash, ensuring a runway of at least 24 months. The company is on track for regulatory filings in the U.S. and Europe in Q3 for setmelanotide in acquired hypothalamic obesity, with the goal of disclosing preliminary results from the Phase II Prader-Willi trial by the end of the year. They remain optimistic about their growth prospects, with IMCIVREE available in over 20 countries and plans to expand further.

Strong Financial Performance

Rhythm Pharmaceuticals reported global revenue for Q2 2025 at $48.5 million, an increase of 29% quarter-over-quarter, with a significant portion coming from U.S. sales. The company also completed an oversubscribed equity offering, raising $189.2 million.

Progress in Clinical Trials

The company reported positive results from the Phase III trial of setmelanotide in acquired hypothalamic obesity, showing a 19.8% reduction in BMI. The Phase II bivamelagon trial also showed promising results with a 9% decrease in BMI in the 600-milligram cohort.

Expansion into International Markets

IMCIVREE is now available in more than 20 countries outside the U.S. for BBS and POMC/LEPR deficiencies, with early access for HO patients in France and Italy.

Increased Prescriptions for IMCIVREE

There was a 38% growth in the cumulative number of BBS prescribers from Q2 2024 to Q2 2025, with a notable increase in prescriptions for pediatric and adolescent patients.

Rhythm Pharmaceuticals (RYTM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RYTM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.71 / -	-0.73	―	―	―
Aug 05, 2025	2025 (Q2)	-0.67 / -0.75	-0.55	-36.36% (-0.20)
May 07, 2025	2025 (Q1)	-0.69 / -0.81	-2.35	65.53% (+1.54)
Feb 26, 2025	2024 (Q4)	-0.69 / -0.72	-0.7	-2.86% (-0.02)
Nov 05, 2024	2024 (Q3)	-0.81 / -0.73	-0.76	3.95% (+0.03)
Aug 06, 2024	2024 (Q2)	-0.71 / -0.55	-0.82	32.93% (+0.27)
May 07, 2024	2024 (Q1)	-2.36 / -2.35	-0.92	-155.43% (-1.43)
Feb 22, 2024	2023 (Q4)	-0.71 / -0.70	-0.75	6.67% (+0.05)
Nov 07, 2023	2023 (Q3)	-0.74 / -0.76	-0.79	3.80% (+0.03)
Aug 01, 2023	2023 (Q2)	-0.80 / -0.82	-0.89	7.87% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RYTM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$90.24	$88.57	-1.85%
May 07, 2025	$62.71	$64.63	+3.06%
Feb 26, 2025	$51.03	$53.32	+4.49%
Nov 05, 2024	$56.25	$62.65	+11.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Rhythm Pharmaceuticals Inc (RYTM) report earnings?

Rhythm Pharmaceuticals Inc (RYTM) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Rhythm Pharmaceuticals Inc (RYTM) earnings time?

Rhythm Pharmaceuticals Inc (RYTM) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RYTM EPS forecast?

RYTM EPS forecast for the fiscal quarter 2025 (Q3) is -0.71.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing